Type 1 diabetes is one of the most challenging autoimmune conditions in modern medicine. The immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreatic islets, leaving the body unable to produce the insulin it needs to regulate blood glucose. Patients therefore depend on lifelong insulin injections or an insulin pump.
Insulin remains essential and lifesaving, but it does not fully reproduce the sophisticated biological regulation of a healthy pancreas. This is precisely why regenerative medicine deserves serious scientific attention.
Over the past two years, I have been exploring the potential of stem cell therapy in my patients, and what I am seeing, particularly in type 1 diabetes, is very encouraging. I believe we need to look beyond conventional approaches and investigate what cellular medicine can offer.
My choice: mesenchymal stem cells (MSCs)
I work exclusively with mesenchymal stem cells (MSCs), particularly those from carefully selected umbilical cord tissue donors. Donor selection and cell quality are fundamental to my approach.
I also apply a specific donor-selection criterion: I select donors who have not received COVID-19 vaccines, because of the spike protein. Vaccination history and the actual presence of detectable spike protein are two different questions, however, and laboratory testing is needed to establish the second. Donor screening, infectious disease testing, cell characterisation, sterility and documented quality control are essential parts of responsible cell therapy. See what the laboratory tests.
How MSCs may help in type 1 diabetes
MSCs are interesting because their potential is not limited to tissue repair. They also have immunomodulatory and paracrine properties: by releasing signalling molecules, growth factors and extracellular vesicles, they influence the inflammatory environment and support tissue repair. In type 1 diabetes, we are investigating several possible mechanisms.
Paracrine signalling
MSCs release biological signals that help reduce inflammation and support the survival and function of the remaining beta cells.
Immunomodulation
MSCs seem to influence immune activity, including regulatory T cells, which may help moderate the autoimmune attack on beta cells.
Tissue protection
Their anti-inflammatory properties help create a better environment for cell recovery and pancreatic function.
MSCs are not the same as insulin-producing pancreatic cells. Their role is mainly supportive and immunomodulatory, rather than directly replacing destroyed beta cells.
What I am seeing in my patients
This is where my interest becomes particularly strong. Over the past two years, I have observed encouraging responses in patients who received mesenchymal stem cell therapy. I am especially interested in patients with type 1 diabetes, because the possibility of improving pancreatic function and metabolic regulation is an important area of investigation.
I am encouraged by the results in my clinical practice. However, these observations must be evaluated with objective measurements, including HbA1c, fasting and stimulated C-peptide, insulin requirements, continuous glucose monitoring and time in range.
Can stem cells cure type 1 diabetes?
This is the question many patients and families understandably ask. My answer is that regenerative medicine offers an exciting possibility. In our clinical work, MSC therapy shows an ability to modulate the autoimmune environment and preserve the remaining beta-cell function. With other approaches, including insulin-producing islet cells derived from stem cells, we are investigating the possibility of replacing the cells that have been destroyed.
Stem cell therapy is not a magic cure, but it offers a real possibility to restore pancreatic function and reduce dependence on insulin.
The challenges ahead
We still need larger clinical trials, standardised cell products, long-term follow-up and objective evidence of lasting benefit. Donor screening, cell viability, potency, sterility, infectious disease testing and proper manufacturing are not optional details; they are essential requirements.
We must also monitor for possible complications, including immune reactions, infection and other treatment-related effects. Scientific progress requires transparency, responsible patient selection and honest reporting of outcomes.
My final thoughts
I have spent years working with stem cells, and I remain convinced that regenerative medicine deserves much greater scientific attention. Type 1 diabetes is an enormous challenge for patients, families and healthcare professionals, and seeing encouraging responses in my own patients gives me a strong reason to keep investigating.
I am not interested in making promises that science cannot yet guarantee. I am interested in exploring possibilities, collecting meaningful clinical evidence and helping patients access responsible advances in medicine.
The future of diabetes treatment may involve more than replacing insulin. It may involve understanding how to protect, restore and regenerate the biological systems that produce it. That is a direction worth pursuing.
Written by Dr. Fermín Celma, general surgeon. Please share this information to help others.